Moderna Receives $32.33 Consensus Price Target from Analysts

Shares of the biotech firm have a 'Reduce' rating from 20 analysts covering the company.

Apr. 5, 2026 at 6:26am

Got story updates? Submit your updates here. ›

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given an average rating of 'Reduce' by the twenty analysts currently covering the company, according to MarketBeat. Five analysts have rated the stock as a 'sell', thirteen have issued a 'hold' rating, and two have assigned a 'buy' rating. The average 12-month price target among brokerages is $33.87.

Why it matters

Moderna's stock performance and analyst sentiment are closely watched as the company's mRNA-based COVID-19 vaccine was the first of its kind to receive emergency use authorization and full approval in multiple countries. The consensus 'Reduce' rating and relatively low average price target suggest analysts see limited upside in the stock at current levels.

The details

Several recent analyst reports have provided updates on Moderna's outlook. The Goldman Sachs Group lifted its price target on Moderna from $36 to $41 and maintained a 'neutral' rating. Evercore set a $35 price objective, while Wall Street Zen upgraded the stock from 'sell' to 'hold'. Citigroup reaffirmed a 'neutral' rating, and UBS Group reiterated a 'neutral' rating with a $36 target price.

  • Moderna reported its latest quarterly earnings on February 13, 2026.

The players

Moderna, Inc.

A biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines.

The Goldman Sachs Group

A multinational investment bank and financial services company.

Evercore

An independent investment banking advisory firm.

Wall Street Zen

A financial research and analysis firm.

Citigroup

A multinational investment bank and financial services corporation.

UBS Group

A Swiss multinational investment bank and financial services company.

Got photos? Submit your photos here. ›

The takeaway

Moderna's stock performance and analyst sentiment reflect the challenges the company faces as it seeks to build on the success of its COVID-19 vaccine. While the company has a promising pipeline of mRNA-based therapies, the 'Reduce' rating and relatively low average price target suggest analysts see limited near-term upside in the stock.